Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease

被引:57
作者
Bavry, Anthony A. [1 ]
Khaliq, Asma
Gong, Yan [2 ]
Handberg, Eileen M.
Cooper-DeHoff, Rhonda M. [2 ]
Pepine, Carl J.
机构
[1] Univ Florida, Dept Med, Div Cardiovasc Med, Coll Med, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL 32610 USA
基金
美国国家卫生研究院;
关键词
Coronary artery disease; Hypertension; Myocardial infarction; Nonsteroidal anti-inflammatory drugs; NSAIDs; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARDIOVASCULAR RISK; MYOCARDIAL-INFARCTION; CYCLO-OXYGENASE-2; INHIBITORS; GASTROINTESTINAL TOXICITY; BLOOD-PRESSURE; NAPROXEN; TRIAL; OSTEOARTHRITIS; CYCLOOXYGENASE;
D O I
10.1016/j.amjmed.2011.02.025
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
BACKGROUND: There is limited information about the safety of chronic nonsteroidal anti-inflammatory drugs (NSAIDs) in hypertensive patients with coronary artery disease. METHODS: This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease. At each visit, patients were asked by the local site investigator if they were currently taking NSAIDs. Patients who reported NSAID use at every visit were defined as chronic NSAID users, while all others (occasional or never users) were defined as nonchronic NSAID users. The primary composite outcome was all-cause death, nonfatal myocardial infarction, or nonfatal stroke. Cox regression was used to construct a multivariate analysis for the primary outcome. RESULTS: There were 882 chronic NSAID users and 21,694 nonchronic NSAID users (n = 14,408 for never users and n = 7286 for intermittent users). At a mean follow-up of 2.7 years, the primary outcome occurred at a rate of 4.4 events per 100 patient-years in the chronic NSAID group, versus 3.7 events per 100 patient-years in the nonchronic NSAID group (adjusted hazard ratio [HR] 1.47; 95% confidence interval [CI], 1.19-1.82; P = .0003). This was due to an increase in cardiovascular mortality (adjusted HR 2.26; 95% CI, 1.70-3.01; P < .0001). CONCLUSION: Among hypertensive patients with coronary artery disease, chronic self-reported use of NSAIDs was associated with an increased risk of adverse events during long-term follow-up. (C) 2011 Elsevier Inc. All rights reserved. The American Journal of Medicine (2011) 124, 614-620
引用
收藏
页码:614 / 620
页数:7
相关论文
共 35 条
[1]
Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association [J].
Antman, Elliott M. ;
Bennett, Joel S. ;
Daugherty, Alan ;
Furberg, Curt ;
Roberts, Harold ;
Taubert, Kathryn A. .
CIRCULATION, 2007, 115 (12) :1634-1642
[2]
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[3]
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis [J].
Becker, Matthew C. ;
Wang, Thomas H. ;
Wisniewski, Lisa ;
Wolski, Kathy ;
Libby, Peter ;
Luescher, Thomas F. ;
Borer, Jeffrey S. ;
Mascette, Alice M. ;
Husni, M. Elaine ;
Solomon, Daniel H. ;
Graham, David Y. ;
Yeomans, Neville D. ;
Krum, Henry ;
Ruschitzka, Frank ;
Lincoff, A. Michael ;
Nissen, Steven E. .
AMERICAN HEART JOURNAL, 2009, 157 (04) :606-612
[4]
NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND GASTROINTESTINAL-DISEASE - PATHOPHYSIOLOGY, TREATMENT AND PREVENTION [J].
BJORKMAN, DJ ;
KIMMEY, MB .
DIGESTIVE DISEASES, 1995, 13 (02) :119-129
[5]
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[6]
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[7]
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects [J].
Capone, ML ;
Sciulli, MG ;
Tacconelli, S ;
Grana, M ;
Ricciotti, E ;
Renda, G ;
Di Gregorio, P ;
Merciaro, G ;
Patrignani, P .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (08) :1295-1301
[8]
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817
[9]
Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events [J].
Chan, AT ;
Manson, JE ;
Albert, CM ;
Chae, CU ;
Rexrode, KM ;
Curhan, GC ;
Rimm, EB ;
Willett, WC ;
Fuchs, CS .
CIRCULATION, 2006, 113 (12) :1578-1587
[10]
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study [J].
Curtis, JP ;
Wang, YF ;
Portnay, EL ;
Masoudi, FA ;
Havranek, EP ;
Krumholz, HM .
BRITISH MEDICAL JOURNAL, 2003, 327 (7427) :1322-1323